Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Period	TotalRevenue
2018-12-31	$67.43M
2019-12-31	$52.61M
2020-12-31	$45.85M
2021-12-31	$50.83M
2022-12-31	$47.68M
2023-12-31	$50.58M
2024-12-31	$57.56M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AQST	$4.17	+0.85%	1.06M
3
4
5

Aquestive Therapeutics Inc. (AQST) Revenue History

Revenue Data

Get Aquestive Therapeutics Inc. Data in Excel

More AQST Financial Data